Search
MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.
Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.
Learn how cancer patients benefit from carefully considered design at Memorial Sloan Kettering, from the director of its design team.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing.
During the AACR COVID-19 and Cancer Meeting, several MSK physicians presented information about providing safe patient care, vaccines, and clinical research.
In February, Harold Varmus' memoir about his life in science was published.
An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.